期刊
TRANSLATIONAL RESEARCH
卷 209, 期 -, 页码 22-38出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.trsl.2019.02.005
关键词
-
资金
- NIH [R01 AA020703, R01 AA24726, U01 AA021856, U01 AA026939, I01BX002213]
- Biomedical Laboratory Research & Development Service of the VA Office of Research and Development
- VA [1I01BX002213-01A2, 735141] Funding Source: Federal RePORTER
Liver cirrhosis is a major cause of morbidity and mortality worldwide. The most common chronic liver diseases in western countries are alcohol-associated liver disease (ALD) and non-alcoholic fatty liver disease (NAFLD). Although these diseases have different causes, liver fibrosis develops via shared mechanisms. The liver and Intestinal microbiome are linked by the portal vein and have bidirectional interactions. Changes in the intestinal microbiome contribute to the pathogenesis and progression of liver diseases including ALD, NAFLD, viral hepatitis and cholestatic disorders, based on studies in patients and animal models. Intestinal microbial dysbiosis has been associated with liver cirrhosis and its complications. We review the mechanisms by which alterations in the microbiome contribute to liver fibrosis and discuss microbiome-based treatment approaches.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据